GlaxoSmithKline announced that the FDA has approved MenHibrix (meningococcal [Groups C and Y] and haemophilus b tetanus toxoid conjugate vaccine). MenHibrix is the first combination vaccine indicated to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b in children aged six weeks through 18 months.

This approval was based on data from clinical trials over a period of seven years in which 7,521 infants and toddlers received at least one dose of MenHibrix. MenHibrix was developed to align with the recommended infant immunization schedule for Hib vaccination and to allow for vaccination against meningococcal groups C and Y without adding additional shots.

The vaccination schedule for MenHibrix is a four-dose series given at two, four, six, and 12–15 months of age.

For more information call (888) 825-5249 or visit